Obstacles to Immunization in Children with Juvenile Idiopathic Arthritis

Image
legacy health gastroenterology :: Article Creator Legacy Health Agrees To $14.5M Settlement Over Claims Nurses, Others ... Legacy Health and its hospitals have agreed to pay $14.5 million to settle a class action suit filed by about 17,000 current and former non-exempt employees who said the health system failed to compensate them for work during meal breaks or performed while technically "off-the-clock,'' the lawsuit alleges. Lawyers for both sides reached the settlement after holding two mediation sessions, according to court records. If you purchase a product or register for an account through a link on our site, we may receive compensation. By using this site, you consent to our User Agreement and agree that your clicks, interactions, and personal information may be collected, recorded, and/or stored by us and social media and other third-party partners in accordance with our Privacy Policy. Legacy Health May Soon Go Out O...

CDSA supports launch of ICMR TB vaccine trial - BSI bureau

This is the first-ever government led vaccine trial after the BCG vaccine trial that was undertaken decades ago. After a detailed land scape analysis of the available vaccine candidates, two potential vaccines were shortlisted for a ICMR led Phase III trial of 12000 healthy house hold contacts of sputum smear positive TB patients.

Clinical Development Services Agency (CDSA), launched by Department of Biotechnology (DBT), Ministry of Science & Technology, Government of India in 2009, has provided study start-up support to all sites and oversaw the recruitment and vaccination of the first participant at National Institute of Tuberculosis and Respiratory Diseases (NITRD) New Delhi on 15th July 2019.

The trial launch at NITRD, Delhi was attended by Dr. Balram Bhargava, Secretary, DHR & Director General, ICMR, Dr. Rohit Sarin – Director, NITRD, Dr. Manjula Singh- Scientist “E” EDC, ITRC-ICMR project team and CDSA team members - Dr. Monika Bahl, Ms. Shubhra Bansal,  Mr. Tarun Puri and Ms. Jinisha Shukla.

Dr. Bhargava emphasised the need in India where the disease is endemic for clinical trials to show that the vaccine is safe and effective. Participants will be recruited from twelve sites in six states—Delhi, Karnataka, Maharashtra, Orissa, Tamil Nadu and Telangana.

CDSA is an extramural unit of Translational Health Science & Technology Institute (THSTI), Faridabad.



https://ift.tt/2YxFE3l

Comments

Popular posts from this blog

180+ chief medical officers to know | 2025

Primary Care - North Greece Internal Medicine & Pediatrics

Screening and Testing for Hepatitis B Virus Infection ...